The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract ...

Gepotidacin is an oral ... and vulvovaginal candidiasis. “The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific ...

The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...

The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025. Blujepa is approved to treat females 12 and older with uncomplicated ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the treatment of uncomplicated urinary tract infections (UTIs) in women aged ...

GSK plc, announced that the US FDA has approved Blujepa (gepotidacin) for the treatment of female adults (=40 kg) and paediatric patients (=12 years, =40 kg) with uncomplicated urinary tract ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials ...